Nureca Limited has announced the dissolution of its wholly owned subsidiary, Nureca Healthcare Private Limited, effective December 3, 2025. This corporate action, carried out under Section 248 of the Companies Act, 2013, marks a significant development in the company's structure.

Key Points of the Announcement

• Subsidiary Dissolved: Nureca Healthcare Private Limited
• Effective Date: December 3, 2025
• Legal Basis: Section 248 of the Companies Act, 2013
• Regulatory Compliance: Informed BSE and NSE as per SEBI regulations

Implications and Context

The striking off of a wholly owned subsidiary often indicates a strategic move by the parent company. While the specific reasons for this action have not been disclosed, such decisions are typically made to streamline operations, reduce administrative overhead, or realign business focus.

Regulatory Compliance

Nureca Limited has adhered to regulatory requirements by promptly informing the stock exchanges. This transparency is crucial for maintaining investor trust and complying with the Securities and Exchange Board of India (SEBI) regulations.

What This Means for Investors

Investors should note that this corporate action might have implications for Nureca Limited's financial structure and operations. However, without further details, it's premature to speculate on the exact impact on the company's future performance or stock value.

Shareholders and potential investors are advised to:

• Monitor any subsequent announcements from the company for additional context
• Review future financial reports to understand any material changes resulting from this dissolution
• Consult with financial advisors if seeking personalized investment advice related to this development

As the market digests this information, it will be important to observe any changes in Nureca Limited's stock performance and analyst recommendations in the coming days.

Nureca Limited , a healthcare and wellness products company, has published its post-buyback public announcement following the Board's approval of a ₹19.14 crore share buyback program, completing key regulatory requirements under SEBI Buyback Regulations.

Buyback Program Details

The Board of Directors approved the buyback program on November 28, 2025, with the company appointing Mefcom Capital Markets Limited as the manager to oversee the buyback process. The program targets up to 5,80,000 equity shares at a maximum price of ₹330.00 per share.

Regulatory Compliance and Publication

Pursuant to Regulation 24(vi) of the SEBI Buyback Regulations, Nureca Limited published its post-buyback public announcement dated December 31, 2025, in multiple newspapers on January 1, 2026. The announcement ensures compliance with regulatory disclosure requirements.

Contact Information and Next Steps

The company has designated Ms. Nishu Kansal, Company Secretary & Compliance Officer, as the authorized contact person for buyback-related queries. Shareholders can reach her at +91 22 4961 6173 or nishu.kansal@nureca.com for further information or clarification regarding the buyback process.

The buyback will be conducted through the stock exchange mechanism on a proportionate basis for eligible shareholders as of the record date. This approach ensures fair participation opportunities for all qualifying shareholders while maintaining transparency in the process.